| News
T3 Pharma wins Swiss Economic Award
06.09.2021
T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss Economic Forum. T3 Pharma has been presented with this award for its cancer therapy based on living bacteria.

Happy faces at T3 Pharma after winning the Swiss Economic Award (img: SPBHNI_THUN)
The Basel-based biotechnology firm T3 Pharmaceuticals has won the Swiss Economic Award 2021, which is organized by the Swiss Economic Forum. It is regarded as the most prestigious young entrepreneur prize in Switzerland. The spin-off from the University of Basel beat off competition from 107 applicants to emerge victorious in the hightech/biotech category. The award comes with prize money of 25,000 Swiss francs.
Founded in 2015, the start-up is active in the area of immuno-oncology, with a focus on the development of a cancer therapy based on living bacteria. T3 Pharma was honored for its innovative approach and outstanding entrepreneurial achievements, according to a press release issued by the University of Basel. The winners receive access to the founder network of the Swiss Economic Forum, among other benefits.
The biotech company’s approach is based on the Type-3 secretion system, via which bacteria can smuggle proteins directly into human cells. According to the information in the press release, T3 Pharma has developed an innovative technology based on this mechanism: the company has successfully optimized the bacteria to accumulate selectively in solid tumors, where they then release therapeutic proteins that directly or indirectly inhibit cancer growth. Clinical trials for the company’s lead product are due to get underway this year.
“We are honored to receive such a prestigious prize from the Swiss Economic Forum,” comments Simon Ittig, CEO of T3 Pharma, in the press release. He adds: “We would like to thank the jury for recognizing the potential of our bacteria-based cancer therapy and our work”.
T3 Pharma has also received support from BaseLaunch, the biotech accelerator operated by the investment and innovation promotion agency Basel Area Business & Innovation. In 2018, the company was named Science Start-Up of the Year by Falling Walls Venture, as one of the first BaseLaunch alumni. A year later, T3 Pharma won the promotional award of the W.A. de Vigier Foundation, which comes with a check for 100,000 Swiss francs.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...
Read MoreRecord figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...
Read MoreNoema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....
Read MoreWhy CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...
Read MoreBasel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...
Read MoreAriceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...
Read More